Literature DB >> 18718480

Opioid receptors: from binding sites to visible molecules in vivo.

Brigitte L Kieffer1, Christopher J Evans.   

Abstract

Opioid drugs such as heroin interact directly with opioid receptors whilst other addictive drugs, including marijuana, alcohol and nicotine indirectly activate endogenous opioid systems to contribute to their rewarding properties. The opioid system therefore plays a key role in addiction neurobiology and continues to be a primary focus for NIDA-supported research. Opioid receptors and their peptide ligands, the endorphins and enkephalins, form an extensive heterogeneous network throughout the central and peripheral nervous system. In addition to reward, opioid drugs regulate many functions such that opioid receptors are targets of choice in several physiological, neurological and psychiatric disorders. Because of the multiplicity and diversity of ligands and receptors, opioid receptors have served as an optimal model for G protein coupled receptor (GPCR) research. The isolation of opioid receptor genes opened the way to molecular manipulations of the receptors, both in artificial systems and in vivo, contributing to our current understanding of the diversity of opioid receptor biology at the behavioral, cellular and molecular levels. This review will briefly summarize some aspects of current knowledge that has accumulated since the very early characterization of opioid receptor genes. Importantly, we will identify a number of research directions that are likely to develop during the next decade.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718480      PMCID: PMC2950281          DOI: 10.1016/j.neuropharm.2008.07.033

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  66 in total

Review 1.  Opioid receptor and peptide gene polymorphisms: potential implications for addictions.

Authors:  K S LaForge; V Yuferov; M J Kreek
Journal:  Eur J Pharmacol       Date:  2000-12-27       Impact factor: 4.432

2.  mu-Opioid receptor knockout mice do not self-administer alcohol.

Authors:  A J Roberts; J S McDonald; C J Heyser; B L Kieffer; H W Matthes; G F Koob; L H Gold
Journal:  J Pharmacol Exp Ther       Date:  2000-06       Impact factor: 4.030

Review 3.  Oligomerization of opioid receptors: generation of novel signaling units.

Authors:  Brandon A R Levac; Brian F O'Dowd; Susan R George
Journal:  Curr Opin Pharmacol       Date:  2002-02       Impact factor: 5.547

Review 4.  Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking.

Authors:  L A Devi
Journal:  Trends Pharmacol Sci       Date:  2001-10       Impact factor: 14.819

5.  Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses.

Authors:  D Filliol; S Ghozland; J Chluba; M Martin; H W Matthes; F Simonin; K Befort; C Gavériaux-Ruff; A Dierich; M LeMeur; O Valverde; R Maldonado; B L Kieffer
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

Review 6.  Structural diversity of G protein-coupled receptors and significance for drug discovery.

Authors:  Malin C Lagerström; Helgi B Schiöth
Journal:  Nat Rev Drug Discov       Date:  2008-04       Impact factor: 84.694

7.  Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors.

Authors:  Sandy Ghozland; Hans W D Matthes; Frederic Simonin; Dominique Filliol; Brigitte L Kieffer; Rafael Maldonado
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

8.  Internalization of mu-opioid receptors produced by etorphine in the rat locus coeruleus.

Authors:  E J Van Bockstaele; K G Commons
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

Review 9.  Exploring the opioid system by gene knockout.

Authors:  Brigitte L Kieffer; Claire Gavériaux-Ruff
Journal:  Prog Neurobiol       Date:  2002-04       Impact factor: 11.685

Review 10.  Agonist-selective mechanisms of GPCR desensitization.

Authors:  E Kelly; C P Bailey; G Henderson
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

View more
  52 in total

1.  Ubiquitination in the first cytoplasmic loop of μ-opioid receptors reveals a hierarchical mechanism of lysosomal down-regulation.

Authors:  James N Hislop; Anastasia G Henry; Mark von Zastrow
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

2.  β-Endorphin antagonizes the effects of α-MSH on food intake and body weight.

Authors:  Roxanne Dutia; Kana Meece; Shveta Dighe; Andrea J Kim; Sharon L Wardlaw
Journal:  Endocrinology       Date:  2012-07-09       Impact factor: 4.736

3.  δ-opioid and dopaminergic processes in accumbens shell modulate the cholinergic control of predictive learning and choice.

Authors:  Vincent Laurent; Jesus Bertran-Gonzalez; Billy C Chieng; Bernard W Balleine
Journal:  J Neurosci       Date:  2014-01-22       Impact factor: 6.167

Review 4.  Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.

Authors:  Ivone Gomes; Wakako Fujita; Moraje V Chandrakala; Lakshmi A Devi
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

5.  Long-term morphine delivery via slow release morphine pellets or osmotic pumps: Plasma concentration, analgesia, and naloxone-precipitated withdrawal.

Authors:  Virginia D McLane; Ivy Bergquist; James Cormier; Deborah J Barlow; Karen L Houseknecht; Edward J Bilsky; Ling Cao
Journal:  Life Sci       Date:  2017-07-16       Impact factor: 5.037

6.  A Genetically Encoded Biosensor Reveals Location Bias of Opioid Drug Action.

Authors:  Miriam Stoeber; Damien Jullié; Braden T Lobingier; Toon Laeremans; Jan Steyaert; Peter W Schiller; Aashish Manglik; Mark von Zastrow
Journal:  Neuron       Date:  2018-05-10       Impact factor: 17.173

7.  Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.

Authors:  Elliott J Sally; Heng Xu; Christina M Dersch; Ling-Wei Hsin; Li-Te Chang; Thomas E Prisinzano; Denise S Simpson; Denise Giuvelis; Kenner C Rice; Arthur E Jacobson; Kejun Cheng; Edward J Bilsky; Richard B Rothman
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

Review 8.  Management of opioid medications in patients with chronic pain and risk of substance misuse.

Authors:  Seddon R Savage
Journal:  Curr Psychiatry Rep       Date:  2009-10       Impact factor: 5.285

9.  Concomitant duplications of opioid peptide and receptor genes before the origin of jawed vertebrates.

Authors:  Görel Sundström; Susanne Dreborg; Dan Larhammar
Journal:  PLoS One       Date:  2010-05-06       Impact factor: 3.240

10.  In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel mu opioid analgesic with reduced propensity to alter motor function.

Authors:  Mariana Spetea; Catalina R Bohotin; Muhammad F Asim; Kurt Stübegger; Helmut Schmidhammer
Journal:  Eur J Pharm Sci       Date:  2010-06-18       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.